LDL Cholesterol

What is LDL Cholesterol?

LDL cholesterol stands for low-density lipoprotein cholesterol, often called “bad” cholesterol. LDL particles are tiny packages that carry cholesterol through your bloodstream to deliver it to cells throughout your body. While your body needs some cholesterol to function properly, problems arise when LDL particles become trapped in the walls of your arteries.[1][2] When LDL particles get stuck in your artery walls, they trigger a process that leads to atherosclerosis—the buildup of fatty deposits called plaques. Over time, these plaques can grow, narrow your arteries, and eventually rupture, causing heart attacks and strokes.[1][2] This is why LDL cholesterol is considered “bad”—not because cholesterol itself is harmful, but because LDL particles are the delivery vehicles that cause plaque buildup when their levels are too high.

The LDL Hypothesis: Why We Know LDL Causes Heart Disease

The evidence that LDL cholesterol causes heart disease is now overwhelming and comes from multiple independent sources that all point to the same conclusion.[1][3] First, genetic studies provide some of the strongest evidence. People born with genetic mutations that cause very high LDL levels (familial hypercholesterolemia) develop heart disease much earlier in life. Those who inherit two copies of these mutations can have heart attacks in their teens or twenties, while those with one copy typically develop heart disease in their 30s and 40s—decades earlier than people with normal LDL levels.[3][4] Conversely, people born with genetic variants that cause naturally lower LDL levels have dramatically lower rates of heart disease throughout their lives.[1][3] Second, large observational studies consistently show a continuous relationship between LDL cholesterol levels and heart disease risk. The higher your LDL, the greater your risk—and this relationship holds true across the entire range of LDL levels studied, with no threshold below which lower isn’t better.[3] Third, randomized clinical trials have proven that lowering LDL cholesterol with medications reduces heart attacks and strokes. The degree of benefit is directly proportional to how much LDL is lowered—the greater the reduction, the greater the protection.[5][1][3]

Cumulative LDL Exposure: It’s Not Just the Number, It’s the Years

One of the most important recent discoveries in cardiovascular medicine is that your risk of heart disease depends not just on your current LDL cholesterol level, but on your total lifetime exposure to LDL—meaning both how high your levels are and how long they stay elevated.[2][6] Think of LDL exposure like water slowly filling a bathtub. Each year you live with elevated LDL is like another year of water flowing into the tub. The higher your LDL level, the faster the water flows. Eventually, the tub overflows—that’s when you’re at significant risk for a heart attack or stroke.[6] Research shows that people who maintain lower LDL levels starting early in life accumulate far less plaque in their arteries and have dramatically lower lifetime risk of cardiovascular events compared to people who only lower their LDL later in life, even if they achieve the same LDL level eventually.[6][7] This is because the plaque that builds up over decades of exposure doesn’t simply disappear when you lower your LDL—it can be stabilized and its growth slowed, but the damage already done remains.[6] Studies of people with genetic variants that cause lifelong lower LDL levels show approximately three times greater protection from heart disease compared to people who lower their LDL by the same amount with medications started in middle age.[6] For example, maintaining an LDL level 40 mg/dL lower throughout your entire life reduces your risk of heart disease by about 80-85%, while lowering LDL by 40 mg/dL with a statin started at age 50 reduces risk by about 25-30%.[6] This cumulative exposure concept explains several important observations. It explains why younger people rarely have heart attacks despite having elevated LDL—they haven’t accumulated enough plaque yet. It explains why heart disease risk accelerates with age—the plaque burden keeps growing. And it explains why people with very high LDL levels develop heart disease so much earlier—their plaque accumulates faster.[6][9] The practical implication is clear: the earlier you lower your LDL cholesterol and the longer you keep it low, the greater your protection from heart disease. Waiting until middle age or later to address elevated LDL means you’ve already accumulated decades of plaque buildup that could have been prevented.[6][2]

How is LDL Cholesterol Measured?

LDL cholesterol is measured through a blood test, usually as part of a standard lipid panel that also measures total cholesterol, HDL cholesterol, and triglycerides.[10] In most cases, LDL cholesterol is calculated using a formula based on your other cholesterol measurements rather than measured directly.[10] Recent evidence shows that fasting is not necessary for most people getting their cholesterol checked—your LDL level remains relatively stable whether you’ve eaten recently or not.[11] However, some laboratories may still request fasting, particularly if your triglycerides are very high.

Understanding Your LDL Cholesterol Numbers

LDL cholesterol is measured in milligrams per deciliter (mg/dL) of blood. Current guidelines focus less on specific target numbers and more on your overall cardiovascular risk and the percentage reduction in LDL achieved with treatment.[12][13] For primary prevention (people without known heart disease):[13][14][12]

• Less than 70 mg/dL: Optimal for most people
• 70-99 mg/dL: Near optimal
• 100-129 mg/dL: Above optimal
• 130-159 mg/dL: Borderline high
• 160-189 mg/dL: High
• 190 mg/dL and above: Very high—treatment with medication is strongly recommended regardless of other risk factors

Frequently asked questions

Why is LDL Cholesterol Testing Important?

Testing your LDL cholesterol is crucial for several reasons: 1. It identifies your current risk. Your LDL level, combined with other factors like age, blood pressure, smoking status, diabetes, and family history, helps determine your overall cardiovascular risk and guides treatment decisions.[13][14][12] 2. It establishes a baseline for tracking. Knowing your LDL level now—and ideally tracking it over time—helps you and your doctor understand your cumulative exposure and monitor whether your prevention strategies are working.[7] 3. It guides treatment intensity. Your LDL level helps determine whether lifestyle changes alone are sufficient or whether medication is needed, and how aggressive treatment should be.[13][14] 4. It’s a proven treatment target. Unlike some risk factors that we can measure but can’t effectively modify, we have safe and effective ways to lower LDL cholesterol, and doing so definitively reduces heart attacks and strokes.[1][3]

A Note About Apolipoprotein B

While LDL cholesterol is the standard measurement, some experts now recommend also measuring apolipoprotein B (apoB), which counts the actual number of LDL particles in your blood rather than just the cholesterol they carry.[18][19][20] Each LDL particle contains exactly one apoB molecule, so measuring apoB tells you how many atherogenic particles you have circulating.[18][21] This can be particularly important because some people have many small, cholesterol-poor LDL particles—their LDL cholesterol might look acceptable, but they actually have a high particle number and therefore higher risk.[18][20] Studies show that apoB often predicts cardiovascular risk more accurately than LDL cholesterol, especially in people with diabetes, metabolic syndrome, high triglycerides, or obesity.[19][20]

How Can I Lower Your LDL Cholesterol?

You can lower LDL cholesterol through a combination of lifestyle changes and, when needed, medications, with diet being the most powerful lifestyle lever. A heart-healthy pattern that reduces saturated fat, increases soluble fiber, favors plant proteins and healthy fats, and pairs with regular exercise, weight control, and smoking cessation can meaningfully improve your lipid profile and overall cardiovascular risk. If lifestyle alone is insufficient, statins are first-line, with ezetimibe, PCSK9 inhibitors, or bempedoic acid as effective add-on or alternative options depending on your risk and tolerance.

References

1. Low-Density Lipoproteins Cause Atherosclerotic Cardiovascular Disease. 1. Evidence From Genetic, Epidemiologic, and Clinical Studies. A Consensus Statement From the European Atherosclerosis Society Consensus Panel. Ference BA, Ginsberg HN, Graham I, et al. European Heart Journal. 2017;38(32):2459-2472. doi:10.1093/eurheartj/ehx144.
2. The LDL Cumulative Exposure Hypothesis: Evidence and Practical Applications. Ference BA, Braunwald E, Catapano AL. Nature Reviews. Cardiology. 2024;21(10):701-716. doi:10.1038/s41569-024-01039-5.
3. Interpretation of the Evidence for the Efficacy and Safety of Statin Therapy. Collins R, Reith C, Emberson J, et al. Lancet (London, England). 2016;388(10059):2532-2561. doi:10.1016/S0140-6736(16)31357-5.
4. LDL Cholesterol: Controversies and Future Therapeutic Directions. Ridker PM. Lancet (London, England). 2014;384(9943):607-617. doi:10.1016/S0140-6736(14)61009-6.
5. Association Between Lowering LDL-C and Cardiovascular Risk Reduction Among Different Therapeutic Interventions: A Systematic Review and Meta-analysis. Silverman MG, Ference BA, Im K, et al. JAMA. 2016;316(12):1289-97. doi:10.1001/jama.2016.13985.
6. Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. Ference BA, Graham I, Tokgozoglu L, Catapano AL. Journal of the American College of Cardiology. 2018;72(10):1141-1156. doi:10.1016/j.jacc.2018.06.046.
7. Association Between Cumulative Low-Density Lipoprotein Cholesterol Exposure During Young Adulthood and Middle Age and Risk of Cardiovascular Events. Zhang Y, Pletcher MJ, Vittinghoff E, et al. JAMA Cardiology. 2021;6(12):1406-1413. doi:10.1001/jamacardio.2021.3508.
8. Non–High-Density Lipoprotein Cholesterol Levels From Childhood to Adulthood and Cardiovascular Disease Events. Wu F, Jacobs DR, Daniels SR, et al. JAMA. 2024;331(21):1834-1844. doi:10.1001/jama.2024.4819.
9. Reprint Of: Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. Ference BA, Graham I, Tokgozoglu L, Catapano AL. Journal of the American College of Cardiology. 2018;72(23 Pt B):2980-2995. doi:10.1016/j.jacc.2018.10.021.
10. Lipid Measurements in the Management of Cardiovascular Diseases: Practical Recommendations a Scientific Statement From the National Lipid Association Writing Group. Wilson PWF, Jacobson TA, Martin SS, et al. Journal of Clinical Lipidology. 2021 Sep-Oct;15(5):629-648. doi:10.1016/j.jacl.2021.09.046.
11. A Test in Context: Lipid Profile, Fasting Versus Nonfasting. Nordestgaard BG. Journal of the American College of Cardiology. 2017;70(13):1637-1646. doi:10.1016/j.jacc.2017.08.006.
12. Lipid Management for the Prevention of Atherosclerotic Cardiovascular Disease. Michos ED, McEvoy JW, Blumenthal RS. The New England Journal of Medicine. 2019;381(16):1557-1567. doi:10.1056/NEJMra1806939.
13. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Grundy SM, Stone NJ, Bailey AL, et al. Journal of the American College of Cardiology. 2019;73(24):3168-3209. doi:10.1016/j.jacc.2018.11.002.
14. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Grundy SM, Stone NJ, Bailey AL, et al. Journal of the American College of Cardiology. 2019;73(24):e285-e350. doi:10.1016/j.jacc.2018.11.003.
15. Cardiovascular, Kidney, and Metabolic Health: An Actionable Vision for Heart Failure Prevention. Ostrominski JW, Cheng AYY, Nelson AJ, et al. Lancet (London, England). 2025;406(10508):1171-1192. doi:10.1016/S0140-6736(25)01384-4.
16. Aggressive LDL-C Lowering and the Brain: Impact on Risk for Dementia and Hemorrhagic Stroke: A Scientific Statement From the American Heart Association. Goldstein LB, Toth PP, Dearborn-Tomazos JL, et al. Arteriosclerosis, Thrombosis, and Vascular Biology. 2023;43(10):e404-e442. doi:10.1161/ATV.0000000000000164.
17. Primary and Secondary Prevention Of Ischemic Stroke and Cerebral Hemorrhage: JACC Focus Seminar. Diener HC, Hankey GJ. Journal of the American College of Cardiology. 2020;75(15):1804-1818. doi:10.1016/j.jacc.2019.12.072.
18. Physiological Bases for the Superiority of Apolipoprotein B Over Low-Density Lipoprotein Cholesterol and Non-High-Density Lipoprotein Cholesterol as a Marker of Cardiovascular Risk. Glavinovic T, Thanassoulis G, de Graaf J, et al. Journal of the American Heart Association. 2022;11(20):e025858. doi:10.1161/JAHA.122.025858.
19. Apolipoprotein B Compared With Low-Density Lipoprotein Cholesterol in the Atherosclerotic Cardiovascular Diseases Risk Assessment. Galimberti F, Casula M, Olmastroni E. Pharmacological Research. 2023;195:106873. doi:10.1016/j.phrs.2023.106873.
20. Excess Apolipoprotein B and Cardiovascular Risk in Women and Men. Johannesen CDL, Langsted A, Nordestgaard BG, Mortensen MB. Journal of the American College of Cardiology. 2024;83(23):2262-2273. doi:10.1016/j.jacc.2024.03.423.